收费全文 | 1971118篇 |
免费 | 150245篇 |
国内免费 | 3545篇 |
耳鼻咽喉 | 29005篇 |
儿科学 | 62524篇 |
妇产科学 | 58136篇 |
基础医学 | 286786篇 |
口腔科学 | 56570篇 |
临床医学 | 170136篇 |
内科学 | 380762篇 |
皮肤病学 | 40421篇 |
神经病学 | 156121篇 |
特种医学 | 77615篇 |
外国民族医学 | 524篇 |
外科学 | 306545篇 |
综合类 | 47121篇 |
现状与发展 | 3篇 |
一般理论 | 539篇 |
预防医学 | 148745篇 |
眼科学 | 46258篇 |
药学 | 149867篇 |
1篇 | |
中国医学 | 3769篇 |
肿瘤学 | 103460篇 |
2018年 | 17885篇 |
2015年 | 17961篇 |
2014年 | 25151篇 |
2013年 | 38466篇 |
2012年 | 52470篇 |
2011年 | 55850篇 |
2010年 | 32797篇 |
2009年 | 30916篇 |
2008年 | 53682篇 |
2007年 | 58357篇 |
2006年 | 58608篇 |
2005年 | 57798篇 |
2004年 | 55960篇 |
2003年 | 54153篇 |
2002年 | 52868篇 |
2001年 | 85017篇 |
2000年 | 87252篇 |
1999年 | 74216篇 |
1998年 | 21743篇 |
1997年 | 19695篇 |
1996年 | 19749篇 |
1995年 | 18674篇 |
1994年 | 17786篇 |
1993年 | 16513篇 |
1992年 | 61361篇 |
1991年 | 60428篇 |
1990年 | 59473篇 |
1989年 | 57738篇 |
1988年 | 53884篇 |
1987年 | 52987篇 |
1986年 | 50593篇 |
1985年 | 48552篇 |
1984年 | 36887篇 |
1983年 | 31922篇 |
1982年 | 19501篇 |
1981年 | 17573篇 |
1980年 | 16355篇 |
1979年 | 35979篇 |
1978年 | 25604篇 |
1977年 | 21829篇 |
1976年 | 20468篇 |
1975年 | 22315篇 |
1974年 | 26931篇 |
1973年 | 26024篇 |
1972年 | 24712篇 |
1971年 | 22920篇 |
1970年 | 21607篇 |
1969年 | 20878篇 |
1968年 | 19351篇 |
1967年 | 17354篇 |
Areas covered: This review includes a view of the clinical classification and risk assessment in children suffering from HL. The chemotherapy more commonly employed is revisited. The use of PET/CT to evaluate the disease in order to guide therapy is analyzed. New options of chemotherapy and emerging immunotherapy are also included.
Expert opinion: In order to make the right treatment choice, a proper initial assessment of risk is mandatory. The choice of therapy in these kinds of patients must be done according to the experience of the team, and also, the cost and logistics related to the eligible scheme are very important. If possible, efforts must be made to include PET/CT in guiding therapy and avoiding overtreatment and long-term adverse effects in children. New options in immunotherapy are emerging and must be considered with caution in selected patients. 相似文献
Objective
To examine whether a healthy weight intervention embedded in the Parents as Teachers (PAT) home visiting program, which was previously found to improve mothers’ body mass index (BMI) and obesity-related behaviors, changed the BMI of preschool children or maternal feeding practices.Methods
This stratified randomized trial included preschool-aged children at risk for overweight whose mothers were overweight or had obesity (n?=?179). The Healthy Eating and Active Living Taught at Home (HEALTH) intervention was based on the Diabetes Prevention Program. Differences were examined using repeated-measures mixed-ANOVA models.Results
Compared with PAT usual care, the HEALTH intervention had no effect on children's BMI or maternal feeding practices. However, combined analyses showed that children's BMI percentile decreased (P??=?.007), BMI z-scores were maintained (P??=?.19), and 3 of 8 feeding practices improved over time (P < .05).Conclusions and Implications
Additional research is needed to assess the effectiveness of PAT to prevent preschool-age obesity using rigorous designs (eg, group-randomized trials) and to identify its active components. HEALTH is ready to be scaled up to prevent maternal weight gain through embedding within the national PAT program. 相似文献Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献![点击此处可从《Journal of the European Academy of Dermatology and Venereology》网站下载免费的PDF全文](/ch/ext_images/free.gif)